Atara Biotherapeutics Securities Fraud Lawsuits
Analysis based on 22 articles · First reported May 01, 2026 · Last updated May 22, 2026
The ongoing securities fraud class action lawsuits against Atara Biotherapeutics are likely to negatively impact its stock price and investor confidence. The legal proceedings could result in significant financial penalties for Atara Biotherapeutics, affecting its business and financial condition.
Multiple law firms, including The Schall Law Firm, Law Offices of Howard G. Smith, Rosen Law Firm, and The Law Offices of Frank R. Cruz, are encouraging investors to join or lead securities fraud class action lawsuits against Atara Biotherapeutics. The lawsuits allege that Atara Biotherapeutics made false and misleading statements between May 20, 2024, and January 9, 2026. Specifically, the company is accused of failing to disclose manufacturing issues and deficiencies in its ALLELE study, which made the United States — Food and Drug Administration's approval of its tabelecleucel BLA unlikely. These issues allegedly overstated tabelecleucel's regulatory prospects and subjected Atara Biotherapeutics to heightened regulatory scrutiny, jeopardizing its clinical trials. Investors who purchased Atara Biotherapeutics securities during the specified 'Class Period' and suffered losses are encouraged to contact these firms before the May 22, 2026, lead plaintiff deadline.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard